By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Cepheid reported after the close of the market Thursday that its second-quarter revenues increased 35 percent as sales of its clinical systems climbed 53 percent year over year.

The Sunnyvale, Calif.-based molecular diagnostics firm brought in total revenues of $67 million for the three-month period ended June 30, compared to $49.6 million for the second quarter of 2010. It easily beat analysts' consensus estimate for revenues of $61 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: researchers classify pancreatic cancer into four subtypes using sequencing, and more.

Genotyping analysis of measles in Ontario indicates the strain there didn't originate from Disneyland or Europe.

The UK Medical Research Council says the proposed path of a new train line could affect research at the Francis Crick Institute.

The House of Lords in the UK approves a bill to allow mitochondrial donation.